Meta-analysis · people
Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophy
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
Across placebo-controlled trials in HIV lipodystrophy, tesamorelin on average lowered deep belly and liver fat and added lean mass, with joint, muscle and injection-site complaints as the side effects seen.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2026
- Journal
- Obes Res Clin Pract
What they tested
The team asked how tesamorelin, compared with placebo, changes body fat, liver fat, metabolic and hormone markers, and side effects in adults with HIV-associated lipodystrophy.
How the study was done
A systematic review and meta-analysis that pooled a small number of randomized controlled trials comparing tesamorelin with placebo (a dummy treatment) in adults with HIV. Databases were searched through July 2025, and results were combined with a random-effects model.

What they found
Compared with placebo, tesamorelin was linked to less visceral fat, the deep fat around the organs (mean difference -27.71 cm²), less trunk fat (-1.18 kg), less limb fat (-0.22 kg), a lower hepatic fat percentage (-4.28%), and a smaller waist (-1.61 cm). Lean body mass rose by 1.42 kg. Subcutaneous fat, the fat just under the skin, and BMI did not drop significantly, and CD4 T-cell counts did not change. Side effects included joint pain, muscle pain, tingling (paresthesia), and injection-site redness, and the authors concluded there were no serious side effects or changes in glucose.
What it doesn’t show
It pools only a handful of trials, all in adults with HIV, so it does not show how tesamorelin works in people without HIV. BMI and subcutaneous fat did not change, so the effect was on specific fat stores rather than on BMI.
The paper
Badran et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026.
The compound
More studies on Tesamorelin
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksRandomized trial · people · 2010
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.